The FDA's Arthritis Advisory Committee (AAC) on Oct. 23 in a 10-4 vote recommended approval of lesinurad, an experimental drug from AstraZeneca plc and its US unit Ardea Biosciences Inc., as a treatment in combination with a xanthine oxidase inhibitor (XOI), such as allopurinol or febuxostat, for hyperuricemia associated with gout in adults.
'Conflicted' Panel Backs AZ Gout Drug; Market Potential?
The FDA's Arthritis Advisory Committee (AAC) on Oct. 23 in a 10-4 vote recommended approval of lesinurad, an experimental drug from AstraZeneca plc and its US unit Ardea Biosciences Inc., as a treatment in combination with a xanthine oxidase inhibitor (XOI), such as allopurinol or febuxostat, for hyperuricemia associated with gout in adults.
More from Immunological
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.